Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950103-21-015270
Filing Date
2021-10-01
Accepted
2021-10-01 17:50:26
Documents
2
Period of Report
2021-10-01

Document Format Files

Seq Description Document Type Size
1 dp159024_3-gline.html 3  
1 dp159024_3-gline.xml 3 12607
2 EXHIBIT 24 dp159024_ex24.htm EX-24 6249
  Complete submission text file 0000950103-21-015270.txt   20227
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Issuer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O UROVANT SCIENCES, INC. 5151 CALIFORNIA AVENUE, SUITE 250 IRVINE CA 92617
Business Address
Gline Matthew (Reporting) CIK: 0001750094 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40782 | Film No.: 211300244